Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Mesembrine alkaloids: Review of their occurrence, chemistry, and pharmacology.

Krstenansky JL.

J Ethnopharmacol. 2017 Jan 4;195:10-19. doi: 10.1016/j.jep.2016.12.004. Epub 2016 Dec 7. Review.

PMID:
27939420
2.

Flavonol and imidazole derivatives block HPV16 E6 activities and reactivate apoptotic pathways in HPV⁺ cells.

Yuan CH, Filippova M, Krstenansky JL, Duerksen-Hughes PJ.

Cell Death Dis. 2016 Jan 21;7:2060. doi: 10.1038/cddis.2015.391.

3.

Analysis of the smoke of cigarettes containing Salvia divinorum.

Krstenansky JL, Muzzio M.

J Anal Toxicol. 2014 Sep;38(7):451-5. doi: 10.1093/jat/bku054. Epub 2014 Jun 7.

PMID:
24908261
4.

Small molecule inhibitors of the HPV16-E6 interaction with caspase 8.

Yuan CH, Filippova M, Tungteakkhun SS, Duerksen-Hughes PJ, Krstenansky JL.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):2125-9. doi: 10.1016/j.bmcl.2011.12.145. Epub 2012 Jan 10.

5.

Adrenochrome and related oxidative metabolites of catecholamines: effects on dopamine neurons and receptor binding profiles.

Krstenansky JL, Xu D, Leitzke R, Saldivar A, Gevorkian R, Shi WX.

Schizophr Res. 2011 Dec;133(1-3):264-5. doi: 10.1016/j.schres.2011.08.015. Epub 2011 Sep 9. No abstract available.

PMID:
21906912
6.

Recent advances in microwave-assisted organic syntheses.

Krstenansky JL, Cotterill I.

Curr Opin Drug Discov Devel. 2000 Jul;3(4):454-61.

PMID:
19649876
7.

Biocatalytic combinatorial synthesis.

Krstenansky JL, Khmelnitsky Y.

Bioorg Med Chem. 1999 Oct;7(10):2157-62.

PMID:
10579520
8.

Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2.

Hemmerich S, Paavola C, Bloom A, Bhakta S, Freedman R, Grunberger D, Krstenansky J, Lee S, McCarley D, Mulkins M, Wong B, Pease J, Mizoue L, Mirzadegan T, Polsky I, Thompson K, Handel TM, Jarnagin K.

Biochemistry. 1999 Oct 5;38(40):13013-25.

PMID:
10529171
9.

Structure-function studies on positions 17, 18, and 21 replacement analogues of glucagon: the importance of charged residues and salt bridges in glucagon biological activity.

Sturm NS, Lin Y, Burley SK, Krstenansky JL, Ahn JM, Azizeh BY, Trivedi D, Hruby VJ.

J Med Chem. 1998 Jul 16;41(15):2693-700.

PMID:
9667960
10.

RS-66271, a C-terminally substituted analog of human parathyroid hormone-related protein (1-34), increases trabecular and cortical bone in ovariectomized, osteopenic rats.

Vickery BH, Avnur Z, Cheng Y, Chiou SS, Leaffer D, Caulfield JP, Kimmel DB, Ho T, Krstenansky JL.

J Bone Miner Res. 1996 Dec;11(12):1943-51.

PMID:
8970897
11.

Combinatorial synthesis of small-molecule libraries using 3-amino-5-hydroxybenzoic acid.

Dankwardt SM, Phan TM, Krstenansky JL.

Mol Divers. 1996 Feb;1(2):113-20.

PMID:
9237200
12.

Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist.

Hegde SS, Bonhaus DW, Stanley W, Eglen RM, Moy TM, Loeb M, Shetty SG, DeSouza A, Krstenansky J.

J Pharmacol Exp Ther. 1995 Dec;275(3):1261-6.

PMID:
8531090
13.

Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1-34), and bovine PTH-(1-34).

Leaffer D, Sweeney M, Kellerman LA, Avnur Z, Krstenansky JL, Vickery BH, Caulfield JP.

Endocrinology. 1995 Aug;136(8):3624-31.

PMID:
7628402
14.

Binding of fluorescent and spin-labeled C-terminal hirudin analogs to thrombin.

Sankarapandi S, Woodford JK, Krstenansky JL, Berliner LJ.

J Med Chem. 1994 Oct 28;37(22):3855-8.

PMID:
7966143
15.
16.

Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor.

Qiu X, Yin M, Padmanabhan KP, Krstenansky JL, Tulinsky A.

J Biol Chem. 1993 Sep 25;268(27):20318-26.

17.
18.

An amphipathic alpha-helical decapeptide in phosphatidylcholine is an effective synthetic lung surfactant.

McLean LR, Lewis JE, Krstenansky JL, Hagaman KA, Cope AS, Olsen KF, Matthews ER, Uhrhammer DC, Owen TJ, Payne MH.

Am Rev Respir Dis. 1993 Feb;147(2):462-5.

PMID:
8430972
19.
20.

Evidence for a lysine-specific fragmentation in fast-atom bombardment mass spectra of peptides.

Ackermann BL, Barbuch RJ, Coutant JE, Krstenansky JL, Owen TJ.

Rapid Commun Mass Spectrom. 1992 Apr;6(4):257-64.

PMID:
1373977
21.

Mixtures of synthetic peptides and dipalmitoylphosphatidylcholine as lung surfactants.

McLean LR, Krstenansky JL, Jackson RL, Hagaman KA, Olsen KA, Lewis JE.

Am J Physiol. 1992 Mar;262(3 Pt 1):L292-300.

PMID:
1550252
22.
23.

Heparin binding properties of the carboxyl terminal domain of [A103,106,108] antistasin 93-119.

Manley GD, Owen TJ, Krstenansky JL, Brankamp RG, Cardin AD.

Adv Exp Med Biol. 1992;313:135-40.

PMID:
1359737
24.

Demonstration that [A103,106,108] antistasin 93-119 inhibits the specific binding of antistasin to sulfatide [Gal(3-SO4)beta 1-1Cer].

Brankamp RG, Manley GD, Owen TJ, Krstenansky JL, Smith PL, Cardin AD.

Biochem Biophys Res Commun. 1991 Nov 27;181(1):246-51.

PMID:
1958194
25.

Examination of the peptide sequence requirements for lipid-binding. Alternative pathways for promoting the interaction of amphipathic alpha-helical peptides with phosphatidylcholine.

McLean LR, Hagaman KA, Owen TJ, Payne MH, Davidson WS, Krstenansky JL.

Biochim Biophys Acta. 1991 Oct 15;1086(1):106-14.

PMID:
1954237
26.

Effect of the hirudin carboxy-terminal peptide 54-65 on the interaction of thrombin with platelets.

Jandrot-Perrus M, Huisse MG, Krstenansky JL, Bezeaud A, Guillin MC.

Thromb Haemost. 1991 Sep 2;66(3):300-5.

PMID:
1746000
27.

Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals.

Broersma RJ, Kutcher LW, Heminger EF, Krstenansky JL, Marshall FN.

Thromb Haemost. 1991 Aug 1;66(2):269. No abstract available.

PMID:
1771625
28.

Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals.

Broersma RJ, Kutcher LW, Heminger EF, Krstenansky JL, Marshall FN.

Thromb Haemost. 1991 Apr 8;65(4):377-81. Erratum in: Thromb Haemost. 1991 Aug 1;66(2):269.

PMID:
2057920
29.
30.

Positional effects of sulfation in hirudin and hirudin PA related anticoagulant peptides.

Payne MH, Krstenansky JL, Yates MT, Mao SJ.

J Med Chem. 1991 Mar;34(3):1184-7.

PMID:
2002458
31.

Structure-function relationships of the C-terminal functional domain of hirudin and its variants.

Krstenansky JL, Mao SJ.

Blood Coagul Fibrinolysis. 1991 Feb;2(1):91-6.

PMID:
1773003
32.

Minimal peptide length for interaction of amphipathic alpha-helical peptides with phosphatidylcholine liposomes.

McLean LR, Hagaman KA, Owen TJ, Krstenansky JL.

Biochemistry. 1991 Jan 8;30(1):31-7. Erratum in: Biochemistry 1991 Nov 12;30(45):11004.

PMID:
1988028
33.

Centrally truncated neuropeptide Y analog acts as an agonist for Y1 receptors on SK-N-MC cells.

Gordon EA, Krstenansky JL, Fishman PH.

Neurosci Lett. 1990 Nov 13;119(2):187-90.

PMID:
2177865
34.

C-terminal modifications of neuropeptide Y and its analogs leading to selectivity for the mouse brain receptor over the porcine spleen receptor.

Krstenansky JL, Owen TJ, Payne MH, Shatzer SA, Buck SH.

Neuropeptides. 1990 Nov;17(3):117-20.

PMID:
1964720
35.

The C-terminal binding domain of hirullin P18. Antithrombin activity and comparison to hirudin peptides.

Krstenansky JL, Owen TJ, Yates MT, Mao SJ.

FEBS Lett. 1990 Sep 3;269(2):425-9. Erratum in: FEBS Lett 1990 Dec 10;276(1-2):232.

36.

Characterization of a monoclonal antibody specific to the amino terminus of the alpha-chain of human fibrin.

Mao SJ, Rechtin AE, Krstenansky JL, Jackson RL.

Thromb Haemost. 1990 Jun 28;63(3):445-8.

PMID:
2402748
37.

Lipid and membrane interactions of neuropeptide Y.

McLean LR, Baron BM, Buck SH, Krstenansky JL.

Biochim Biophys Acta. 1990 May 9;1024(1):1-4.

PMID:
2159800
38.

Development of MDL 28,050, a small stable antithrombin agent based on a functional domain of the leech protein, hirudin.

Krstenansky JL, Broersma RJ, Owen TJ, Payne MH, Yates MT, Mao SJ.

Thromb Haemost. 1990 Apr 12;63(2):208-14.

PMID:
2363122
40.

Signal epitopes in the three-dimensional structure of neuropeptide Y. Interaction with Y1, Y2, and pancreatic polypeptide receptors.

Schwartz TW, Fuhlendorff J, Kjems LL, Kristensen MS, Vervelde M, O'Hare M, Krstenansky JL, Bjørnholm B.

Ann N Y Acad Sci. 1990;611:35-47. No abstract available.

PMID:
2174222
41.

Effect of micelle diameter on tryptophan dynamics in an amphipathic helical peptide in phosphatidylcholine.

McLean LR, Krstenansky JL, Owen TJ, Eftink MR, Hagaman KA.

Biochemistry. 1989 Oct 17;28(21):8403-10.

PMID:
2605192
42.

Preparation of antibodies to a synthetic C terminus of hirudin and identification of an antigenic site.

Mao SJ, Yates MT, Owen TJ, Krstenansky JL.

J Immunol Methods. 1989 Jun 2;120(1):45-50.

PMID:
2471745
43.

Centrally truncated and stabilized porcine neuropeptide Y analogs: design, synthesis, and mouse brain receptor binding.

Krstenansky JL, Owen TJ, Buck SH, Hagaman KA, McLean LR.

Proc Natl Acad Sci U S A. 1989 Jun;86(12):4377-81.

44.

C-terminal peptide alcohol, acid and amide analogs of desulfato hirudin54-65 as antithrombin agents.

Krstenansky JL, Payne MH, Owen TJ, Yates MT, Mao SJ.

Thromb Res. 1989 May 15;54(4):319-25.

PMID:
2763270
45.

Short model peptides having a high alpha-helical tendency: design and solution properties.

Krstenansky JL, Owen TJ, Hagaman KA, McLean LR.

FEBS Lett. 1989 Jan 2;242(2):409-13.

46.

A heparin which binds to the envelope glycoprotein gp120 inhibits human immunodeficiency virus replication.

Cardin AD, Taylor DL, Krstenansky JL, Tyms AS, Jackson RL.

Trans Assoc Am Physicians. 1989;102:101-9. No abstract available.

PMID:
2561637
47.
48.

Importance of the C-terminal alpha-helical structure for glucagon's biological activity.

Krstenansky JL, Zechel C, Trivedi D, Hruby VJ.

Int J Pept Protein Res. 1988 Dec;32(6):468-75.

PMID:
2854536
50.

Interaction of hirudin with thrombin: identification of a minimal binding domain of hirudin that inhibits clotting activity.

Mao SJ, Yates MT, Owen TJ, Krstenansky JL.

Biochemistry. 1988 Oct 18;27(21):8170-3.

PMID:
3233202

Supplemental Content

Loading ...
Support Center